7h agoSeeking AlphaBULLISH 74Product/PR
Alvotech wins FDA nod for new manufacturing process for Humira biosimilar
Alvotech (ALVO) stock gains as the FDA OKs new manufacturing process for Simlandi, the company
Archived explainer. For the current picture see today's ALVO page.
Why Is ALVOTECH (ALVO) Stock Up Today?
By the Top Tier Newswire AI Desk · October 20, 2026 at 9:33 AM ET · reviewed against 6 wire stories
ALVOTECH (ALVO) is up +7.31% in the latest session. Our newswire has captured 6 stories on ALVO across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Alvotech shares rose 7.31% to $5.40 on Tuesday, driven by the U.S. Food and Drug Administration’s approval of a new manufacturing process for its Humira biosimilar, SIMLANDI. The regulatory nod allows the company to more than double drug substance output per batch at its Reykjavik facility, a significant operational improvement for the biotechnology firm.
What Happened
Alvotech announced that the FDA approved its "Process 2.0" manufacturing method for SIMLANDI (adalimumab-ryvk) in the DSM2 suite located in Reykjavik, Iceland. The company stated that this change more than doubles drug substance output per batch without altering the upstream manufacturing scale. This approval represents a key efficiency gain for the global biotechnology company, which specializes in developing and manufacturing biosimilar medicines. The news was widely covered across financial media, with reports highlighting the immediate positive reaction in the stock market following the announcement.
What The Data Shows
The stock opened at $5.50, marking a 9.4% gap up from the prior close of $5.03. Intraday trading saw the stock hit a session high of $5.60 at 9:00 AM ET and a low of $5.34 at 7:45 AM ET, closing the session at $5.35. Volume stood at 0.2 million shares, which is 0.2 times the three-month daily average. Fundamentally, Alvotech has a market capitalization of $1.8 billion and remains unprofitable, with a trailing twelve-month EPS of -0.61 and a net margin of -36.3%. Revenue declined 12.1% over the same period. The stock has a beta of 0.20 and a 52-week range of $2.94 to $8.74. Over the last eight sessions, the stock had fallen 11.3% from $5.67 to $5.03 before this move. The session marked a fresh 52-week high for the ticker.
What To Watch
Investors will monitor how the increased manufacturing capacity impacts future revenue growth and cost structures. With the stock printing a new 52-week high, attention will likely turn to whether the company can sustain this momentum amid its current unprofitable status and declining revenue trend.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALVO by the numbers
Last: $5.40Session: +7.31%7 sessions: -11.29%Coverage: 6 stories / 5 sourcesAI sentiment: 70/100 (bullish)Mkt cap: $1.8B52w: $2.94 to $8.74
The headlines behind the move
8h agoMarketChameleonBULLISH 64Product/PR
Alvotech Wins FDA Nod for SIMLANDI Process 2.0 That More Than Doubles Output Per Batch October 20, 2026
Alvotech said the FDA approved a new “Process 2.0” manufacturing process for SIMLANDI (adalimumab-ryvk) in its DSM2 suite in Reykjavik, Iceland. The company said the change more than doubles drug substance output per batch without changing upstream scale, while maintaining comparability and product quality. Management highlighted that fewer batches for the same quantity can free capacity for other portfolio products and improve flexibility as biosimilar demand grows.
9h agoThe FlyBULLISH 74Product/PR
Alvotech announces FDA approval for new Simlandi manufacturing process
9h agoInvesting.com MarketsBULLISH 62General
Why is Alvotech stock climbing today?
Why is Alvotech stock climbing today?
10h agoInvesting.com MarketsBULLISH 74Product/PR
Alvotech shares jump premarket after FDA approves new Simlandi process
Alvotech shares jump premarket after FDA approves new Simlandi process
10h agoBusiness InsiderBULLISH 74Product/PR
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ALVO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALVO move explainers: 2026-10-20 · 2026-10-06 · 2026-10-05 · 2026-09-16 · 2026-08-31